SEC Filing Summary: Pro-Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on September 13, 2007, by Pro-Pharmaceuticals, Inc. (Note: The request metadata references "Galectin Therapeutics Inc," but the filing text explicitly identifies the registrant as Pro-Pharmaceuticals, Inc.). The report addresses a regulatory matter concerning the company's listing status on the American Stock Exchange (Amex).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt. However, it references the following financial conditions that triggered regulatory review:
- Stockholders' equity was below $2 million.
- The company reported losses in two of its last three fiscal years.
Material Changes and Events
On June 22, 2007, the Amex notified the company that it was non-compliant with continued listing standards due to the financial metrics noted above. On September 13, 2007, the Amex Staff accepted the company's plan of compliance and granted an extension until October 13, 2008, to regain compliance. The company is subject to periodic review during this extension period.
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting from the American Stock Exchange. If the company fails to make progress consistent with its compliance plan or fails to regain compliance by the October 13, 2008 deadline, it could be delisted. No specific financial guidance or management commentary regarding future operations was included in this filing.
Investor Verification Checklist
- Verify the current stockholders' equity and profitability status to assess progress toward the October 2008 compliance deadline.
- Confirm the company's continued listing status on the American Stock Exchange.
- Review the specific details of the "plan of compliance" submitted on July 23, 2007, to understand the milestones required to avoid delisting.
- Check for any subsequent filings regarding periodic reviews by Amex Staff.